TOP > 外国特許検索 > ACUTE RENAL FAILURE-SPECIFIC BIOMARKER, ACUTE RENAL FAILURE DIAGNOSIS METHOD, ACUTE RENAL FAILURE TEST KIT, ANIMAL TREATMENT METHOD AND ACUTE RENAL FAILURE MEDICATION

ACUTE RENAL FAILURE-SPECIFIC BIOMARKER, ACUTE RENAL FAILURE DIAGNOSIS METHOD, ACUTE RENAL FAILURE TEST KIT, ANIMAL TREATMENT METHOD AND ACUTE RENAL FAILURE MEDICATION

Foreign code F210010297
File No. S2018-1076-C0
Posted date 2021年1月28日
Country 世界知的所有権機関(WIPO)
International application number 2019JP039227
International publication number WO 2020071518
Date of international filing 令和元年10月4日(2019.10.4)
Date of international publication 令和2年4月9日(2020.4.9)
Priority data
  • 特願2018-188746 (2018.10.4) JP
Title ACUTE RENAL FAILURE-SPECIFIC BIOMARKER, ACUTE RENAL FAILURE DIAGNOSIS METHOD, ACUTE RENAL FAILURE TEST KIT, ANIMAL TREATMENT METHOD AND ACUTE RENAL FAILURE MEDICATION
Abstract Provided is a biomarker capable of specifically diagnosing acute renal failure. The acute renal failure-specific biomarker is miRNA which is primarily present in blood. The miRNA is miRNA-5100. Furthermore, it is possible to use this miRNA-5100 as a method for diagnosing acute renal failure. When making a diagnosis, acute renal failure is diagnosed when miRNA-5100 expression in the blood decreases. As a kit for testing for acute renal failure, it is possible to include a reagent which measures miRNA-5100.
Outline of related art and contending technology BACKGROUND ART
Acute renal failure (Acute kidney injury, AKI) is, the infectious disease, medication, such as after surgery and acute renal dysfunction occurs, are largely responsible for the prognosis of a patient's life. Acute renal failure (AKI) is, in a short period of several hours to several days is reduced renal function rapidly in a disease. Urine excretion of waste products from unavailable, or to overflow. Dialysis and may be required.
Conventional, acute renal failure (Kidney Disease: Improving Global Outcomes) KDIGO diagnostic guidelines are provided. This KDIGO classification, urine and serum creatinine Acute renal failure is increased based on the decrease in the amount has been diagnosed.
Specifically, (KDIGO for acute renal failure diagnosis guideline, AKI (stage) of the classification stage, defined by any of the following: one or more serum creatinine value within 1. 48 to 0.3mg/dl to increase the serum creatinine value within the previous 2. has been found that 7 or 1.5 times or more the expected base value if there is an increase in the urine over a period of time 3. 6 0.5ml/kg/amount is reduced to
However, this reference has already been missed in the timing of therapeutic intervention in many cases. For this reason, the development of a biomarker for acute renal failure has been desired.
Incidentally, in recent years, a variety (microRNA, micro RNA) miRNA involved in the disease, early diagnosis of disease is effective as a biomarker has been reported. Referring to Patent Document 1, as an example of a conventional biomarker, chronic diabetic status of the indication of the miRNA is described.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • JICHI MEDICAL UNIVERSITY
  • Inventor
  • MORISHITA, Yoshiyuki
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、「問合せ先」までご連絡ください。

PAGE TOP

close
close
close
close
close
close